Blackstone buys Takeda’s medication unit in Japan for $2.3bn
Blackstone is flush with cash as investors continue to bet big on the firm as it shifts investments to businesses likely to benefit from Covid-related consumer behaviour
24 August 2020 - 17:23
Tokyo — Takeda Pharmaceutical agreed to sell its Japanese consumer health-care business for ¥242bn ($2.3bn) to Blackstone, which plans to take the over-the-counter medication unit public in about five years.
For the drugmaker, the sale represents another piece of its plan to dispose of $10bn in assets after its $62bn mega-acquisition of Shire in 2019...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.